Continuous-infusion vinblastine in refractory carcinoma of the cervix: a phase II trial.
Twenty patients with recurrent or metastatic squamous cell carcinoma of the cervix were treated with continuous-infusion vinblastine sulfate. Two patients (10%) had partial responses of 4 and 7 months' duration. Neutropenia was dose limiting. Vinblastine sulfate given by continuous infusion has limited activity in this malignancy.